United States Patent and Trademark Office - Sales Receipt -

Adjustment date: 09/08/2005 FMERCER 09/06/2005 FMERCER 00000002 021065

10789900

01 FC:2814 65.00 CR VIA FAX TO: (571) 273-8300 (in Duplicate)

PTO/SB/25 (09-04) Approved for use through 07/3 t/2005. (MB 0531-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unloss it displays a valid OMB control number. TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING Docket Number (Optional) REJECTION OVER A PENDING "REFERENCE" APPLICATION 02-027 CIP In re Application of: ERIC J. BECKMAN et. al. Application No.: 10/789,900 Filed: FEBRUARY 27, 2004 FOR SYNTHESIS OF N-VINYL FORMAMIDE percent interest in the instant application hereby discraims LINIVERSITY OF PITTSBURGH except as provided below, the terminal part of the statutory term of any patient granted on the instant application which would extend beyond the expiration date of the full statutory term of any patient of an expiration of the full statutory term of any patient granted on personne Application Number 10/852.104 the deed on AUGUST 29, 2003, as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patient granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patient on the pending reference application. The owner hereby agrees that any patient so granted on the instant application shall be enforceable only for and during such period that it and any patient granted on the reference application are commonly owned. This agreement runs with any patient granted on the instant application and is binding upon the grantee, its successors or assigns. In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said reference application, "as the term of any patent granted on said reference application may be shortened by any terminal disclaimer fied prior to the grant of any patent on the pending reference application." In the event that any such patent; granted on the pending reference application; application expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant. Check either box 1 or 2 below, if appropriate 1 For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. wby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful felse statements and the like so made are purishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful felse statements may jeopardize the validity of the application or any patent issued thereon. 2. The undersigned is an attorney or agent of record. Reg. No. 34,772 19789988 88888885 821865 88/19/2085 NBIHAS Henry E. Bartomy ( 65.88 DA 82 FC:2814 August 18, 2005 HENRY E. BARTONY, JR. Typed or printed name (412) 338-8632 Telephone Number Terminal disclaimer fee under 37 CFR 1.20(d) is included. The Commissioner for Patients is hereby authorized to charge the fee under Section 1.20(d) to USPTO Deposit Account 02-1065. A duplicate copy of this Terminal Disclaimer is provided herewith. WARNING: Information on this form may become public. Credit eard information should not be included on this form. Provide credit card information and authorization on PTO-2038. "Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). "Statoment under 37 GPR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).

Form PTO/SS/96 may be used for making this statement. See MPEP § 324.

This collection of information is required by 37 GPR 1.321. The information is required by obtain or rotain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentistly is governed by 35 U.S.C. 122 and 37 GPR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, indusing gethering, preparing, and estimating the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on this amount of tims you require to complete trist form another suggestions for roducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Comments, P.O. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1459. Alexandria, VA 22313-1450.

If you need assistance in complating the form, call 1-800-PTQ-9199 and select option 2.

PAGE 619 \* RCVD AT 8/18/2005 8;39:33 AM (Eastern Daylight Time) \* SVR:USPTO-EFXRF-6/26 \* DNIS-2738300 \* CSED:14123386611 \* DURATION (mm-ss):02-48

2814-65